Who are Retapamulin (Altabax)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Linezolid (L), Erythromycin, Azithromycin , Clarithromycin, Linezolid Injectable Product, Linezolid (LZD), PRISTINAMYCIN XRP7263, Azithromycin Ophthalmic Solution, 1%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/retapamulin-altabax.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Retapamulin (Altabax) — Competitive Intelligence Brief

Retapamulin (Altabax) (Retapamulin (Altabax)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pleuromutilin antibiotic. Area: Infectious Disease / Dermatology.

marketed Pleuromutilin antibiotic Bacterial 50S ribosomal subunit Infectious Disease / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Retapamulin (Altabax) (Retapamulin (Altabax)) — The University of Texas Health Science Center, Houston. Retapamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing bacterial growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Retapamulin (Altabax) TARGET	Retapamulin (Altabax)	The University of Texas Health Science Center, Houston	marketed	Pleuromutilin antibiotic	Bacterial 50S ribosomal subunit
Linezolid (L)	Linezolid (L)	Shenzhen Third People's Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Erythromycin, Azithromycin , Clarithromycin	Erythromycin, Azithromycin , Clarithromycin	Baqiyatallah Medical Sciences University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Linezolid Injectable Product	Linezolid Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Linezolid (LZD)	Linezolid (LZD)	Wuhan Pulmonary Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
PRISTINAMYCIN XRP7263	PRISTINAMYCIN XRP7263	Sanofi	marketed	Macrolide antibiotic / Streptogramin	Bacterial 50S ribosomal subunit
Azithromycin Ophthalmic Solution, 1%	Azithromycin Ophthalmic Solution, 1%	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pleuromutilin antibiotic class)

St. Luke's-Roosevelt Hospital Center · 1 drug in this class
Stiefel, a GSK Company · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Retapamulin (Altabax) — Competitive Intelligence Brief. https://druglandscape.com/ci/retapamulin-altabax. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab